MAY 27 2027
Zenas BioPharma — obexelimab $ZBIO
for IgG4-related disease
About
IgG4-related disease is a chronic inflammatory condition where the immune system infiltrates tissues with specific cells, often causing scarring. Obexelimab is an antibody designed to bind to and block the function of certain immune cells that drive this harmful inflammation. By quieting this overactive immune response, the drug could potentially prevent disease flare-ups and reduce tissue damage.
Pivotal trial
This study aims to examine the efficacy and safety of obexelimab for the prevention of flare of IgG4-related disease (IgG4-RD)
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on obexelimab
- Zenas BioPharma announces new data from Phase 3 INDIGO trial on obexelimab - TipRanks
- Zenas Biopharma Announces Upcoming Presentations Of Obexelimab Data In Igg4-Related Disease At The Igg4ward! 6Th International Symposium On Igg4-Related Disease And Acr Convergence 2026 - tradingview.com
- Zenas BioPharma to present obexelimab IgG4-RD trial data - Investing.com
- ZBIO: Obexelimab nears FDA decision as pivotal data and commercial plans drive growth in autoimmune therapies - tradingview.com
- ZBIO: Obexelimab nears FDA decision as key data and commercial plans advance for autoimmune pipeline - tradingview.com
Sponsor Watch — recent news on Zenas BioPharma
- Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026
- Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event
- Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Zenas BioPharma Bear Case Overlooks Obexelimab's Commercial Potential, Wedbush Says